|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Lion Biotechnologies, Inc.
| | | Phone: | 650-260-7120 | Year Established: | 2013 | Ticker: | LBIO | Exchange: | NASDAQ | Main Contact: | Maria Fardis, PhD, MBA, President & CEO | | Other Contacts: | Steven Fischkoff, MD, CMO Michael T. Lotze, MD, CSO
| | Company Description | Lion Biotechnologies, formed through the merger of Lion with Genesis Biopharma, is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company’s lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TIL) for the treatment of patients with Stage 4 metastatic melanoma, and is based on a clinical Cooperative Research and Development Agreement with the National Cancer Institute. TIL therapy is also being evaluated in physician-sponsored clinical trials at MD Anderson Cancer Center and the H. Lee Moffitt Cancer Center & Research Institute. | |
|
|
|
|
|